Month: June 2020

FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the “Company”) announces the closing of a previously announced private placement of 1,500,000 of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share and warrants to purchase 1,500,000 Shares (cumulatively, the “Securities”) of the Company to certain institutional investors for gross proceeds, before deducting placement fees and other estimated offering expenses payable by the Company, of approximately C$10.125 million. The warrants have a five-year term and an exercise price of C$9.65 per share. read more

FSD Pharma Inc. Announces C$10.125 Million Private Placement

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (NASDAQ: HUGE) CSE;HUGE or the “Company”), today announced it has entered into definitive agreements with certain institutional investors for the purchase and sale of 1,500,000 shares of the Company’s Class B Subordinate Voting Shares (“Shares”) at a price of C$6.75 per Share pursuant to a private placement resulting in gross proceeds of approximately C$10.125 million. The Company has also agreed to issue common share purchase warrants to purchase 1,500,000 Shares of the Company. The warrants will have a five year-term and an exercise price of C$9.65 per share. The closing of the offering is expected to occur on or about June 8, 2020, subject to the satisfaction of customary closing conditions including applicable exchange approvals.  The Company has granted the investors an option to acquire up to an additional C$10.125 million of units on the terms set forth above for a period of 30 days following the initial closing. read more

FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA)  to treat COVID-19, the disease caused by the SARS-CoV-2 virus. Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients. read more

Millennial Lithium Corp. Granted Final REMSA License at its Pastos Grandes Project, Salta, Argentina

MotherlodeTV
V.ML, Millenial Lithium, lithium, Argentina

Millennial Lithium Corp. (TSXV: ML) (FSE: A3N2) (OTCQX: MLNLF) (“Millennial” or the “Company”) is pleased to announce that the Mining Court of Salta has granted Millennial’s Argentine subsidiary, Proyecto Pastos Grandes S.A., the remaining mining license, Nueva Sijesyta 01, that comprised the original REMSA Properties. The REMSA Properties are comprised of 5 mining licenses totaling 6557 ha which are contiguous with Millennial’s core licenses covering the Salar de Pastos Grandes. The Company has implemented operational procedures to protect the health of its office staff, field crews and contractors during the COVID-19 global pandemic. Where possible, office staff, field crews and contractors have been working from home per local government advisories. Plans for field and other work for 2020 will be evaluated on an ongoing basis but at this time, Millennial does not anticipate a significant or material impact upon its operations. Millennial’s operations in Salta Province are classified as essential and are exempted from some many local and federal COVID-19 restrictions in Argentina. read more